Tertius News is an AI-native newsroom: an AI model reads the source articles linked below — on this story, all of them from one outlet — and extracts what that outlet reported, claim by claim. How this works →

Drug company backdown sees lifesaving cancer treatment offered for free

AstraZeneca has reversed its earlier decision to withdraw the breast cancer and endometriosis drug Zoladex from Australia, pledging to supply it free to patients with no alternative treatments. The reversal follows widespread criticism and a petition with over 42,000 signatures. Pharmaceutical commentator Paul Cross suggests international pricing strategies may have influenced the company's decision.

By Tertius News AI Desk 1 outlet · 2 articles Version 1 Coverage Jul 29, 2026 Published Aug 14

AstraZeneca Reverses Decision, Will Supply Zoladex Free to Australian Patients Indefinitely

Women with breast cancer or endometriosis in Australia will continue to have access to the drug Zoladex, after pharmaceutical company AstraZeneca reversed its earlier plan to withdraw the medication. The company announced it will supply the drug free of charge to patients who have no alternative treatments, according to the ABC.

AstraZeneca had previously said it would remove Zoladex, a goserelin 3.6mg implant used to treat breast cancer and endometriosis, from both the Pharmaceutical Benefits Scheme (PBS) and the private market in November. The company cited the Australian price for the product as being too low, making it "unsustainable to supply the medicine on the PBS."

The decision drew criticism from patient advocates, patients, and the public. A Change.org petition calling for urgent action gathered more than 42,000 signatures within weeks, as reported by the ABC.

Initially, AstraZeneca had proposed a six-month access program offering the medication for free to those without alternative treatments. However, the company has since committed to supplying the medication indefinitely to patients whose doctors determine no other suitable treatments are available. An AstraZeneca spokesperson said this includes patients currently prescribed the implant and those who may need it after 1 November 2026.

Pharmaceutical commentator Paul Cross suggested that the nature of pricing negotiations may make it more financially advantageous for AstraZeneca to supply Zoladex in Australia for free rather than set a low pricing precedent for other countries. He noted that international reference pricing, where governments use lower prices in other countries as a negotiating benchmark, was likely a factor behind the company's decision to remove Zoladex from the PBS. Cross said it was possible the company's decision to provide the drug for free was influenced by these broader pricing considerations.

Before the reversal, the ABC reported speaking with several women who were considering removing their ovaries because they feared going without the drug. The last-minute change ensures continued access for these and other affected patients.

How this outlet told it

ABC Australia as of Jul 29, 2026, 8:01 PM UTC

Framing: Pharmaceutical company bows to pressure, commits to supplying lifesaving drug — Informative, with a tone of relief and criticism towards the pharmaceutical company

Facts Included:

AstraZeneca will supply Zoladex indefinitely to patients with no alternative treatments
The drug was initially set to be pulled from the PBS and private market in November
A Change.org petition gathered over 42,000 signatures in support of continued access to the drug
Patients who cannot afford the private market price of $700 per dose will have access to the drug for free
The Pharmaceutical Benefits Advisory Committee will discuss listing an alternative medication, triptorelin

Read the source article →

ABC Australia as of Jul 29, 2026, 7:01 PM UTC

Framing: Pharmaceutical company bows to pressure, commits to supplying lifesaving drug — Informative, with a tone of relief and criticism towards the pharmaceutical company

Facts Included:

AstraZeneca will supply Zoladex indefinitely to patients with no alternative treatments
The drug was initially set to be pulled from the PBS and private market in November
A Change.org petition gathered over 42,000 signatures in support of continued access to the drug
Patients who cannot afford the private market price of $700 per dose will have access to the drug for free
The Pharmaceutical Benefits Advisory Committee will discuss listing an alternative medication, triptorelin

Read the source article →

What was claimed, and who backed it

Each row is one claim, attributed to the outlet whose wording states it most clearly. Confidence rates how directly the source text states the claim — explicit and unhedged rates high; hedged, pieced-together, or internally inconsistent statements rate lower. It does not measure whether the claim is true. Status counts the distinct outlets we found asserting it — so a single-source claim can still show high confidence, and a multi-source claim can show medium. Every one of those outlets is named beside the status, so you can check the count against the list. For claims extracted before we began storing that list, the row says so: it names the outlet the claim is quoted from and states that we have not recorded which outlets backed it. Outlets wrote at different times, so a figure that evolves — a casualty count, for example — can legitimately differ between rows; check the "as of" time next to each claim's source.

Claim	Confidence	Status
ClaimAstraZeneca will supply Zoladex indefinitely to patients with no alternative treatments.	ConfidenceHigh	StatusSingle-source via ABC Australia as of Jul 29, 2026, 8:01 PM UTC
ClaimThe drug was initially set to be pulled from the PBS and private market in November.	ConfidenceHigh	StatusSingle-source via ABC Australia as of Jul 29, 2026, 8:01 PM UTC
ClaimA Change.org petition gathered over 42,000 signatures in support of continued access to the drug.	ConfidenceHigh	StatusSingle-source via ABC Australia as of Jul 29, 2026, 8:01 PM UTC
ClaimPatients who cannot afford the private market price of $700 per dose will have access to the drug for free.	ConfidenceHigh	StatusSingle-source via ABC Australia as of Jul 29, 2026, 8:01 PM UTC
ClaimThe Pharmaceutical Benefits Advisory Committee will discuss listing an alternative medication, triptorelin.	ConfidenceHigh	StatusSingle-source via ABC Australia as of Jul 29, 2026, 8:01 PM UTC
ClaimInternational reference pricing has been a feature of the global pharmaceutical industry for many years.	ConfidenceMedium	StatusSingle-source via ABC Australia as of Jul 29, 2026, 8:01 PM UTC
ClaimAustralia could become increasingly vulnerable to decisions made to keep prices high overseas.	ConfidenceMedium	StatusSingle-source via ABC Australia as of Jul 29, 2026, 8:01 PM UTC
ClaimThe government is working through the recommendations of the HTA review to provide faster access to medicines and therapies.	ConfidenceHigh	StatusSingle-source via ABC Australia as of Jul 29, 2026, 8:01 PM UTC

Transparency & Audit Trail

1 outlet · 2 articles consulted: ABC Australia 8 claims extracted Version 1 Written 2026-08-14